• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by RLX Technology Inc.

    3/29/22 8:51:15 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email
    SC 13G 1 tm227281d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934*
     
    RLX Technology Inc.
    (Name of Issuer)
     
    Class A ordinary shares, par value of $0.00001 per share
    (Title of Class of Securities)
     
    74969N 103**
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         ¨ Rule 13d-1(b)
     
         ¨ Rule 13d-1(c)
     
         x Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    ** CUSIP number 74969N 103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are listed on the New York Stock Exchange under the symbol “RLX.” Each ADS represents one Class A ordinary share, par value US$0.00001 per share.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

    Deep Technology Linkage Fund L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    140,523,240

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    140,523,240

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    140,523,240

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.95%

    12

    TYPE OF REPORTING PERSON

    PN

           

     

     

     

    1

    NAMES OF REPORTING PERSONS

    Llex Holdings Limited*

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    140,523,240

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    140,523,240

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    140,523,240

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.95%

    12

    TYPE OF REPORTING PERSON

    FI

           

    * Llex Holdings Limited is the general partner of Deep Technology Linkage Fund L.P..

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

    Source Code Super Holdings Co.*

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    140,778,031**

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    140,778,031**

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    140,778,031**

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.96%

    12

    TYPE OF REPORTING PERSON

    FI

           

    * Source Code Super Holdings Co. is the sole shareholder of Llex Holdings Limited. Llex Holdings Limited is the general partner of Deep Technology Linkage Fund L.P..

     

    ** Include (i) 140,523,240 Class A ordinary shares held by Deep Technology Linkage Fund L.P. and (ii) 254,791 Class A ordinary shares held by an affiliate of Deep Technology Linkage Fund L.P., of which Source Code Super Holdings Co. is the sole shareholder.

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

    Whealth Holdings Limited*

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    British Virgin Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    140,778,031**

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    140,778,031**

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    140,778,031**

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.96%

    12

    TYPE OF REPORTING PERSON

    FI

           

    * Whealth Holdings Limited beneficially owns Source Code Super Holdings Co.. Source Code Super Holdings Co. is the sole shareholder of Llex Holdings Limited. Llex Holdings Limited is the general partner of Deep Technology Linkage Fund L.P..

     

    ** Include (i) 140,523,240 Class A ordinary shares held by Deep Technology Linkage Fund L.P. and (ii) 254,791 Class A ordinary shares held by an affiliate of Deep Technology Linkage Fund L.P., of which Source Code Super Holdings Co. is the sole shareholder.

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

    Enlightenment Trust*

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    The Island of Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    140,778,031**

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    140,778,031**

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    140,778,031**

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.96%

    12

    TYPE OF REPORTING PERSON

    FI

           

    * Enlightenment Trust ultimately wholly owns Whealth Holdings Limited. Whealth Holdings Limited beneficially owns Source Code Super Holdings Co.. Source Code Super Holdings Co. is the sole shareholder of Llex Holdings Limited. Llex Holdings Limited is the general partner of Deep Technology Linkage Fund L.P..

     

    Mr. Charlie Cao and his family members are the beneficiaries of Enlightenment Trust. Mr. Cao and his family members disclaim beneficial ownership of the Issuer’s Class A ordinary shares held by Deep Technology Linkage Fund L.P., except to the extent of their pecuniary interest in these shares. Trident Trust Company Limited is the trustee of Enlightenment Trust.

     

    ** Include (i) 140,523,240 Class A ordinary shares held by Deep Technology Linkage Fund L.P. and (ii) 254,791 Class A ordinary shares held by an affiliate of Deep Technology Linkage Fund L.P., of which Source Code Super Holdings Co. is the sole shareholder.

     

     

     

     

    ITEM 1(a). NAME OF ISSUER:

     

    RLX Technology Inc. (the “Issuer”)

     

    ITEM 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    19/F, Building 1, Junhao Central Park Plaza

    No. 10 South Chaoyang Park Avenue

    Chaoyang District, Beijing 100026

    People’s Republic of China

     

    ITEM 2(a). NAME OF PERSON FILING:

     

      (i) Deep Technology Linkage Fund L.P.

      (ii) Llex Holdings Limited

      (iii) Source Code Super Holdings Co.

      (iv) Whealth Holdings Limited

      (v) Enlightenment Trust

     

    (collectively, the “Reporting Persons”)

     

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE:

     

    For each of the Reporting Persons:

     

      (i) Deep Technology Linkage Fund L.P. - Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbou r Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands

     

      (ii) Llex Holdings Limited  - Cayman Islands  - Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbou r Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands

     

      (iii) Source Code Super Holdings Co. - Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbou r Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands

     

      (iv) Whealth Holdings Limited  - Start Chambers, Wickham's Cay II, P.O. Box 2221, Road Town, Tortola, British Virgin Island

     

      (v) Enlightenment Trust - 11 Bath Street, St Helier, JE4 8UT, Jersey

     

    ITEM 2(c). CITIZENSHIP:

     

      (i) Deep Technology Linkage Fund L.P. - Cayman Islands

      (ii) Llex Holdings Limited  - Cayman Islands  - Cayman Islands

      (iii) Source Code Super Holdings Co. - Cayman Islands

      (iv) Whealth Holdings Limited  - British Virgin Islands

      (v) Enlightenment Trust - the Island of Jersey

     

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

     

    Class A ordinary shares, par value of $0.00001 per share.

     

    ITEM 2(e). CUSIP NO.:

     

    74969N 103

     

     

     

     

    ITEM 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d -2(b) or (c), check whether the persons filing is a:

     

    Not applicable

     

    ITEM 4. OWNERSHIP

     

    The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentages set forth in this Schedule 13G are calculated based upon 1,570,790,570 ordinary shares issued and outstanding as of April 16, 2021, including 952,618,780 Class A ordinary shares and 618,171,790 Class B ordinary shares, which was reported in the Issuer’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on April 23, 2021.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

     

    Not applicable

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    Not applicable

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

    ITEM 10. CERTIFICATIONS

     

    Not applicable

     

     

     

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
    99.1 Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    March 29, 2022

     

    Deep Technology Linkage Fund L.P.  
       
    /s/ Charlie Cao  
    Name: Charlie Cao  
    Title: Authorized Representative  

     

    Llex Holdings Limited  
       
    /s/ Charlie Cao  
    Name: Charlie Cao  
    Title: Authorized Representative  

     

    Source Code Super Holdings Co.  
       
    /s/ Charlie Cao  
    Name: Charlie Cao  
    Title: Authorized Representative  
       

     

    Whealth Holdings Limited  
       
    /s/ Charlie Cao  
    Name: Charlie Cao  
    Title: Authorized Representative  

     

    Enlightenment Trust  
       
    /s/ Karen E Eeles & Anne-Marie Crompton  
    Name: Karen E Eeles & Anne-Marie Crompton  
    Title: Authorized Representatives of Trident Trust Company Limited  

     

     

     

    Get the next $RLX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Second Quarter 2025 Financial Results on August 22, 2025

    - Earnings Call Scheduled for 8:00 a.m. ET on August 22, 2025 - SHENZHEN, China, Aug. 5, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2025, before the U.S. markets open on Friday, August 22, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 22, 2025 (8:00 PM Beijing/Hong Kong Time on August 22, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Ko

    8/5/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited First Quarter 2025 Financial Results

    SHENZHEN, China, May 16, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Net revenues were RMB808.3 million (US$111.4 million) in the first quarter of 2025, compared with RMB551.6 million in the same period of 2024.Gross margin was 28.6% in the first quarter of 2025, compared with 25.9% in the same period of 2024.U.S. GAAP net income was RMB222.7 million (US$30.7 million) in the first quarter of 2025, compared with RMB132.6 million in the same period of 2024.Non-GAAP net income[1

    5/16/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    5/16/25 6:02:23 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 20-F filed by RLX Technology Inc.

    20-F - RLX Technology Inc. (0001828365) (Filer)

    4/17/25 4:01:47 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Second Quarter 2025 Financial Results on August 22, 2025

    - Earnings Call Scheduled for 8:00 a.m. ET on August 22, 2025 - SHENZHEN, China, Aug. 5, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2025, before the U.S. markets open on Friday, August 22, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 22, 2025 (8:00 PM Beijing/Hong Kong Time on August 22, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Ko

    8/5/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited First Quarter 2025 Financial Results

    SHENZHEN, China, May 16, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Net revenues were RMB808.3 million (US$111.4 million) in the first quarter of 2025, compared with RMB551.6 million in the same period of 2024.Gross margin was 28.6% in the first quarter of 2025, compared with 25.9% in the same period of 2024.U.S. GAAP net income was RMB222.7 million (US$30.7 million) in the first quarter of 2025, compared with RMB132.6 million in the same period of 2024.Non-GAAP net income[1

    5/16/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care